Advances and challenges of liposome assisted drug delivery

Frontiers in Pharmacology

Volumn 6, Issue DEC, 2015, Pages

  Sercombe, Lisa ^a,b   Veerati, Tejaswi ^c,d   Moheimani, Fatemeh ^a,b   Wu, Sherry Y ^c   Sood, Anil K ^c   Hua, Susan ^a,b  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d RICE UNIVERSITY   (United States)

Author keywords

Accelerated blood clearance; Biological challenges; Complement activation related pseudoallergy; Drug delivery; Lipid based drug delivery system; Liposomes; Nanotechnology; Translation

Indexed keywords

AMIKACIN; AMPHOTERICIN B; ANNAMYCIN; BORTEZOMIB; CAMPTOTHECIN DERIVATIVE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; IRINOTECAN; LIPOSOME; LURTOTECAN; MITOXANTRONE; MORPHINE SULFATE; NAVELBINE; NYSTATIN; OPSONIN; PACLITAXEL; RETINOIC ACID; SMALL INTERFERING RNA; TOPOTECAN; VERTEPORFIN; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADVANCED CANCER; BONE CANCER; BRAIN CANCER; BREAST CANCER; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL PRACTICE; COLORECTAL CANCER; COMPLEMENT ACTIVATION; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; ENCAPSULATION; HEAD AND NECK CANCER; HUMAN; LEUKEMIA; LIVER TUMOR; LUNG CANCER; LUNG INFECTION; MENINGITIS; METASTATIC COLORECTAL CANCER; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; MYCOSIS; NONHODGKIN LYMPHOMA; NONHUMAN; OPSONIZATION; OVARY CANCER; PAIN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; PLASMA CLEARANCE; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; RETICULOENDOTHELIAL SYSTEM; REVIEW; SOLID TUMOR; TRIPLE NEGATIVE BREAST CANCER;

EID: 84953274760     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2015.00286     Document Type: Review

References (129)

1. Allen, T. M. (1994). Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol. Sci. 15, 215-220. doi: 10.1016/0165-6147(94)90314-X
2. Allen, T. M., and Cullis, P. R. (2004). Drug delivery systems: entering the mainstream. Science 303, 1818-1822. doi: 10.1126/science.1095833
3. Allen, T. M., and Cullis, P. R. (2013). Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 65, 36-48. doi: 10.1016/j.addr.2012.09.037
4. Andresen, T. L., Davidsen, J., Begtrup, M., Mouritsen, O. G., and Jørgensen, K. (2004). Enzymatic release of antitumor ether lipids by specific phospholipase A2 activation of liposome-forming prodrugs. J. Med. Chem. 47, 1694-1703. doi: 10.1021/jm031029r
5. Antohe, F., Lin, L., Kao, G. Y., Poznansky, M. J., and Allen, T. M. (2004). Transendothelial movement of liposomes in vitro mediated by cancer cells, neutrophils or histamine. J. Liposome Res. 14, 1-25. doi: 10.1081/LPR-120039660
6. Antoni, L., Nuding, S., Wehkamp, J., and Stange, E. F. (2014). Intestinal barrier in inflammatory bowel disease. World J. Gastroenterol. 20, 1165-1179. doi: 10.3748/wjg.v20.i5.1165
7. Awada, A., Bondarenko, I. N., Bonneterre, J., Nowara, E., Ferrero, J. M., Bakshi, A. V., et al. (2014). A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC). Ann. Oncol. 25, 824-831. doi: 10.1093/annonc/mdu025
8. Bendas, G. (2001). Immunoliposomes: a promising approach to targeting cancer therapy. BioDrugs 15, 215-224. doi: 10.2165/00063030-200115040-00002
9. Bibi, S., Lattmann, E., Mohammed, A. R., and Perrie, Y. (2012). Trigger release liposome systems: local and remote controlled delivery? J. Microencapsul. 29, 262-276. doi: 10.3109/02652048.2011.646330
10. Bozzuto, G., and Molinari, A. (2015). Liposomes as nanomedical devices. Int. J. Nanomedicine 10, 975-999. doi: 10.2147/IJN.S68861
11. Campbell, R. B., Fukumura, D., Brown, E. B., Mazzola, L. M., Izumi, Y., Jain, R. K., et al. (2002). Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res. 62, 6831-6836.
12. Campbell, R. B., Ying, B., Kuesters, G. M., and Hemphill, R. (2009). Fighting cancer: from the bench to bedside using second generation cationic liposomal therapeutics. J. Pharm. Sci. 98, 411-429. doi: 10.1002/jps.21458
13. Carlson, M., Raab, Y., Peterson, C., Hällgren, R., and Venge, P. (1999). Increased intraluminal release of eosinophil granule proteins EPO, ECP, EPX, and cytokines in ulcerative colitis and proctitis in segmental perfusion. Am. J. Gastroenterol. 94, 1876-1883. doi: 10.1111/j.1572-0241.1999.01223.x
14. Chandrasekar, P. (2008). Amphotericin B lipid complex: treatment of invasive fungal infections in patients refractory to or intolerant of amphotericin B deoxycholate. Ther. Clin. Risk Manag. 4, 1285-1294.
15. Chang, H. I., and Yeh, M. K. (2012). Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int. J. Nanomedicine 7, 49-60. doi: 10.2147/IJN.S26766
16. Chang, T. C., Shiah, H. S., Yang, C. H., Yeh, K. H., Cheng, A. L., Shen, B. N., et al. (2015). Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients. Cancer Chemother. Pharmacol. 75, 579-586. doi: 10.1007/s00280-014-2671-x
17. Charron, D. M., Chen, J., and Zheng, G. (2015). Theranostic lipid nanoparticles for cancer medicine. Cancer Treat. Res. 166, 103-127. doi: 10.1007/978-3-319-16555-4_5
18. Chrai, S. S., Murari, R., and Ahmad, I. (2002). Liposomes (a review) part two: drug delivery systems. BioPharm 17, 40-43.
19. Clancy, J. P., Dupont, L., Konstan, M. W., Billings, J., Fustik, S., Goss, C. H., et al. (2013). Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax 68, 818-825. doi: 10.1136/thoraxjnl-2012-202230
20. Coco, R., Plapied, L., Pourcelle, V., Jérôme, C., Brayden, D. J., Schneider, Y. J., et al. (2013). Drug delivery to inflamed colon by nanoparticles: comparison of different strategies. Int. J. Pharm. 440, 3-12. doi: 10.1016/j.ijpharm.2012.07.017
21. Cole, J. T., and Holland, N. B. (2015). Multifunctional nanoparticles for use in theranostic applications. Drug Deliv. Transl. Res. 5, 295-309. doi: 10.1007/s13346-015-0218-2
22. Cullis, P. R., Chonn, A., and Semple, S. C. (1998). Interactions of liposomes and lipid-based carrier systems with blood proteins: relation to clearance behaviour in vivo. Adv. Drug Deliv. Rev. 32, 3-17.
23. Dams, E. T., Laverman, P., Oyen, W. J., Storm, G., Scherphof, G. L., van Der Meer, J. W., et al. (2000). Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J. Pharmacol. Exp. Ther. 292, 1071-1079.
24. Dark, G. G., Calvert, A. H., Grimshaw, R., Poole, C., Swenerton, K., Kaye, S., et al. (2005). Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group. J. Clin. Oncol. 23, 1859-1866. doi: 10.1200/JCO.2005.02.028
25. Dempsey, P. W., Allison, M. E., Akkaraju, S., Goodnow, C. C., and Fearon, D. T. (1996). C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271, 348-350. doi: 10.1126/science.271.5247.348
26. Deshpande, P. P., Biswas, S., and Torchilin, V. P. (2013). Current trends in the use of liposomes for tumor targeting. Nanomedicine (Lond). 8, 1509-1528. doi: 10.2217/nnm.13.118
27. Dicheva, B. M., ten Hagen, T. L., Li, L., Schipper, D., Seynhaeve, A. L., van Rhoon, G. C., et al. (2013). Cationic thermosensitive liposomes: a novel dual targeted heat-triggered drug delivery approach for endothelial and tumor cells. Nano Lett. 13, 2324-2331. doi: 10.1021/nl3014154
28. Dicheva, B. M., ten Hagen, T. L., Schipper, D., Seynhaeve, A. L., van Rhoon, G. C., Eggermont, A. M., et al. (2014). Targeted and heat-triggered doxorubicin delivery to tumors by dual targeted cationic thermosensitive liposomes. J. Control. Release 195, 37-48. doi: 10.1016/j.jconrel.2014.07.058
29. Ding, B. S., Dziubla, T., Shuvaev, V. V., Muro, S., and Muzykantov, V. R. (2006). Advanced drug delivery systems that target the vascular endothelium. Mol. Interv. 6, 98-112. doi: 10.1124/mi.6.2.7
30. Felgner, P. L., Gadek, T. R., Holm, M., Roman, R., Chan, H. W., Wenz, M., et al. (1987). Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. U.S.A. 84, 7413-7417. doi: 10.1073/pnas.84.21.7413
31. Ferrari, M. (2005). Nanovector therapeutics. Curr. Opin. Chem. Biol. 9, 343-346. doi: 10.1016/j.cbpa.2005.06.001
32. Fetterly, G. J., Grasela, T. H., Sherman, J. W., Dul, J. L., Grahn, A., Lecomte, D., et al. (2008). Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel. Clin. Cancer Res. 14, 5856-5863. doi: 10.1158/1078-0432.CCR-08-1046
33. Gabizon, A. A., Barenholz, Y., and Bialer, M. (1993). Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm. Res. 10, 703-708. doi: 10.1023/A:1018907715905
34. Gabizon, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., et al. (1994). Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 54, 987-992.
35. Gabizon, A., Chisin, R., Amselem, S., Druckmann, S., Cohen, R., Goren, D., et al. (1991). Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. Br. J. Cancer 64, 1125-1132. doi: 10.1038/bjc.1991.476
36. Gabizon, A., Dagan, A., Goren, D., Barenholz, Y., and Fuks, Z. (1982). Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice. Cancer Res. 42, 4734-4739.
37. Gabizon, A., Horowitz, A. T., Goren, D., Tzemach, D., Shmeeda, H., and Zalipsky, S. (2003). In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. Clin. Cancer Res. 9, 6551-6559.
38. Gabizon, A., Tzemach, D., Mak, L., Bronstein, M., and Horowitz, A. T. (2002). Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models. J. Drug Target. 10, 539-548. doi: 10.1080/1061186021000072447
39. Geng, S., Yang, B., Wang, G., Qin, G., Wada, S., and Wang, J. Y. (2014). Two cholesterol derivative-based PEGylated liposomes as drug delivery system, study on pharmacokinetics and drug delivery to retina. Nanotechnology 25:275103. doi: 10.1088/0957-4484/25/27/275103
40. Giannella, M., Ercolani, G., Cristini, F., Morelli, M., Bartoletti, M., Bertuzzo, V., et al. (2015). High-dose weekly liposomal amphotericin b antifungal prophylaxis in patients undergoing liver transplantation: a prospective phase II trial. Transplantation 99, 848-854. doi: 10.1097/TP.0000000000000393
41. Gross, N., Ranjbar, M., Evers, C., Hua, J., Martin, G., Schulze, B., et al. (2013). Choroidal neovascularization reduced by targeted drug delivery with cationic liposome-encapsulated paclitaxel or targeted photodynamic therapy with verteporfin encapsulated in cationic liposomes. Mol. Vis. 19, 54-61.
42. Guo, X., and Szoka, F. C. Jr. (2003). Chemical approaches to triggerable lipid vesicles for drug and gene delivery. Acc. Chem. Res. 36, 335-341. doi: 10.1021/ar9703241
43. Han, X. J., Wei, Y. F., Wan, Y. Y., Jiang, L. P., Zhang, J. F., and Xin, H. B. (2014). Development of a novel liposomal nanodelivery system for bioluminescence imaging and targeted drug delivery in ErbB2-overexpressing metastatic ovarian carcinoma. Int. J. Mol. Med. 34, 1225-1232. doi: 10.3892/ijmm.2014.1922
44. Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., et al. (2000). Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 156, 1363-1380. doi: 10.1016/S0002-9440(10)65006-7
45. Hua, S. (2013). Targeting sites of inflammation: intercellular adhesion molecule-1 as a target for novel inflammatory therapies. Front. Pharmacol. 4:127. doi: 10.3389/fphar.2013.00127
46. Hua, S., and Cabot, P. J. (2013). Targeted nanoparticles that mimic immune cells in pain control inducing analgesic and anti-inflammatory actions: a potential novel treatment of acute and chronic pain condition. Pain Physician. 16, E199-E216.
47. Hua, S., Marks, E., Schneider, J. J., and Keely, S. (2015). Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue. Nanomedicine 11, 1117-1132. doi: 10.1016/j.nano.2015.02.018
48. Hua, S., and Wu, S. Y. (2013). The use of lipid-based nanocarriers for targeted pain therapies. Front. Pharmacol. 4:143. doi: 10.3389/fphar.2013.00143
49. Immordino, M. L., Dosio, F., and Cattel, L. (2006). Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomedicine 1, 297-315.
50. Ishida, T., Harada, M., Wang, X. Y., Ichihara, M., Irimura, K., and Kiwada, H. (2005). Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes. J. Control. Release 105, 305-317. doi: 10.1016/j.jconrel.2005.04.003
51. Ishida, T., Harashima, H., and Kiwada, H. (2001a). Interactions of liposomes with cells in vitro and in vivo: opsonins and receptors. Curr. Drug Metab. 2, 397-409. doi: 10.2174/1389200013338306
52. Ishida, T., Ichihara, M., Wang, X., and Kiwada, H. (2006a). Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes. J. Control. Release 115, 243-250. doi: 10.1016/j.jconrel.2006.08.001
53. Ishida, T., Ichihara, M., Wang, X., Yamamoto, K., Kimura, J., Majima, E., et al. (2006b). Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J. Control. Release 112, 15-25. doi: 10.1016/j.jconrel.2006.01.005
54. Ishida, T., Kirchmeier, M. J., Moase, E. H., Zalipsky, S., and Allen, T. M. (2001b). Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells. Biochim. Biophys. Acta 1515, 144-158. doi: 10.1016/S0005-2736(01)00409-6
55. Ishida, T., and Kiwada, H. (2008). Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int. J. Pharm. 354, 56-62. doi: 10.1016/j.ijpharm.2007.11.005
56. Ishida, T., Masuda, K., Ichikawa, T., Ichihara, M., Irimura, K., and Kiwada, H. (2003). Accelerated clearance of a second injection of PEGylated liposomes in mice. Int. J. Pharm. 255, 167-174. doi: 10.1016/S0378-5173(03)00085-1
57. Jaafar-Maalej, C., Elaissari, A., and Fessi, H. (2012). Lipid-based carriers: manufacturing and applications for pulmonary route. Expert Opin. Drug Deliv. 9, 1111-1127. doi: 10.1517/17425247.2012.702751
58. Jahn, F., Jordan, K., Behlendorf, T., Globig, C., Schmoll, H. J., Müller-Tidow, C., et al. (2015). Safety and efficacy of liposomal cytarabine in the treatment of neoplastic meningitis. Oncology 89, 137-142. doi: 10.1159/000380913
59. Kirpotin, D. B., Drummond, D. C., Shao, Y., Shalaby, M. R., Hong, K., Nielsen, U. B., et al. (2006). Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 66, 6732-6740. doi: 10.1158/0008-5472.CAN-05-4199
60. Kirpotin, D., Park, J. W., Hong, K., Zalipsky, S., Li, W. L., Carter, P., et al. (1997). Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochem. Mosc. 36, 66-75. doi: 10.1021/bi962148u
61. Klimuk, S. K., Semple, S. C., Scherrer, P., and Hope, M. J. (1999). Contact hypersensitivity: a simple model for the characterization of disease-site targeting by liposomes. Biochim. Biophys. Acta 1417, 191-201. doi: 10.1016/S0005-2736(98)00261-2
62. Koning, G. A., and Storm, G. (2003). Targeted drug delivery systems for the intracellular delivery of macromolecular drugs. Drug Discov. Today 8, 482-483. doi: 10.1016/S1359-6446(03)02699-0
63. Kono, K. (2001). Thermosensitive polymer-modified liposomes. Adv. Drug Deliv. Rev. 53, 307-319. doi: 10.1016/S0169-409X(01)00204-6
64. Kraft, J. C., Freeling, J. P., Wang, Z., and Ho, R. J. (2014). Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. J. Pharm. Sci. 103, 29-52. doi: 10.1002/jps.23773
65. Kunstfeld, R., Wickenhauser, G., Michaelis, U., Teifel, M., Umek, W., Naujoks, K., et al. (2003). Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model. J. Invest. Dermatol. 120, 476-482. doi: 10.1046/j.1523-1747.2003.12057.x
66. Larsson, J. M., Karlsson, H., Sjövall, H., and Hansson, G. C. (2009). A complex, but uniform O-glycosylation of the human MUC2 mucin from colonic biopsies analyzed by nanoLC/MSn. Glycobiology 19, 756-766. doi: 10.1093/glycob/cwp048
67. Laverman, P., Boerman, O. C., Oyen, W. J., Dams, E. T., Storm, G., and Corstens, F. H. (1999). Liposomes for scintigraphic detection of infection and inflammation. Adv. Drug Deliv. Rev. 37, 225-235.
68. Laverman, P., Carstens, M. G., Storm, G., and Moghimi, S. M. (2001). Recognition and clearance of methoxypoly(ethyleneglycol)2000-grafted liposomes by macrophages with enhanced phagocytic capacity. Implications in experimental and clinical oncology. Biochim. Biophys. Acta 1526, 227-229. doi: 10.1016/S0304-4165(01)00142-8
69. Löhr, J. M., Haas, S. L., Bechstein, W. O., Bodoky, G., Cwiertka, K., Fischbach, W., et al. (2012). Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial. Ann. Oncol. 23, 1214-1222. doi: 10.1093/annonc/mdr379
70. Lv, H., Zhang, S., Wang, B., Cui, S., and Yan, J. (2006). Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control. Release 114, 100-109. doi: 10.1016/j.jconrel.2006.04.014
71. Lyass, O., Uziely, B., Ben-Yosef, R., Tzemach, D., Heshing, N. I., Lotem, M., et al. (2000). Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 89, 1037-1047. doi: 10.1002/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z
72. Mangala, L. S., Han, H. D., Lopez-Berestein, G., and Sood, A. K. (2009). Liposomal siRNA for ovarian cancer. Methods Mol. Biol. 555, 29-42. doi: 10.1007/978-1-60327-295-7_3
73. Maruyama, K. (2002). PEG-immunoliposome. Biosci. Rep. 22, 251-266. doi: 10.1023/A:1020138622686
74. Metselaar, J. M., and Storm, G. (2005). Liposomes in the treatment of inflammatory disorders. Expert Opin. Drug Deliv. 465-76. doi: 10.1517/17425247.2.3.465
75. Moghimi, S. M., Hamad, I., Andresen, T. L., Jørgensen, K., and Szebeni, J. (2006). Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. FASEB J. 20, 2591-2593. doi: 10.1096/fj.06-6186fje
76. Moghimi, S. M., and Hunter, A. C. (2001). Capture of stealth nanoparticles by the body's defences. Crit. Rev. Ther. Drug Carrier Syst. 18, 527-550. doi: 10.1615/CritRevTherDrugCarrierSyst.v18.i6.30
77. Moghimi, S. M., and Szebeni, J. (2003). Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res. 42, 463-478. doi: 10.1016/S0163-7827(03)00033-X
78. Monteiro, N., Martins, A., Reis, R. L., and Neves, N. M. (2014). Liposomes in tissue engineering and regenerative medicine. J. R. Soc. Interface 11:20140459. doi: 10.1098/rsif.2014.0459
79. Murday, J. S., Siegel, R. W., Stein, J., and Wright, J. F. (2009). Translational nanomedicine: status assessment and opportunities. Nanomedicine 5, 251-273. doi: 10.1016/j.nano.2009.06.001
80. Narang, A. S., Chang, R. K., and Hussain, M. A. (2013). Pharmaceutical development and regulatory considerations for nanoparticles and nanoparticulate drug delivery systems. J. Pharm. Sci. 102, 3867-3882. doi: 10.1002/jps.23691
81. Needham, D., Anyarambhatla, G., Kong, G., and Dewhirst, M. W. (2000). A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res. 60, 1197-1201.
82. Nehoff, H., Parayath, N. N., Domanovitch, L., Taurin, S., and Greish, K. (2014). Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect. Int. J. Nanomedicine 9, 2539-2555. doi: 10.2147/IJN.S47129
83. Ning, Y. M., He, K., Dagher, R., Sridhara, R., Farrell, A. T., Justice, R., et al. (2007). Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma. Oncology (Williston Park) 21, 1503-1508. discussion: 11, 13, 16 passim.
84. Noble, C. O., Kirpotin, D. B., Hayes, M. E., Mamot, C., Hong, K., Park, J. W., et al. (2004). Development of ligand-targeted liposomes for cancer therapy. Expert Opin. Ther. Targets 8, 335-353. doi: 10.1517/14728222.8.4.335
85. Northfelt, D. W., Martin, F. J., Working, P., Volberding, P. A., Russell, J., Newman, M., et al. (1996). Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J. Clin. Pharmacol. 36, 55-63. doi: 10.1002/j.1552-4604.1996.tb04152.x
86. Offner, F., Krcmery, V., Boogaerts, M., Doyen, C., Engelhard, D., Ribaud, P., et al. (2004). Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B. Antimicrob. Agents Chemother. 48, 4808-4812. doi: 10.1128/AAC.48.12.4808-4812.2004
87. Oku, N., and Namba, Y. (1994). Long-circulating liposomes. Crit. Rev. Ther. Drug Carrier Syst. 11, 231-270.
88. Olivier, K. N., Shaw, P. A., Glaser, T. S., Bhattacharyya, D., Fleshner, M., Brewer, C. C., et al. (2014). Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. Ann. Am. Thorac. Soc. 11, 30-35. doi: 10.1513/AnnalsATS.201307-231OC
89. Ozpolat, B., Lopez-Berestein, G., Adamson, P., Fu, C. J., and Williams, A. H. (2003). Pharmacokinetics of intravenously administered liposomal all-trans-retinoic acid (ATRA) and orally administered ATRA in healthy volunteers. J. Pharm. Pharm. Sci. 6, 292-301.
90. Park, J. W., Hong, K., Kirpotin, D. B., Colbern, G., Shalaby, R., Baselga, J., et al. (2002). Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res. 8, 1172-1181.
91. Peterson, C. G., Eklund, E., Taha, Y., Raab, Y., and Carlson, M. (2002). A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal levels and clinical application in patients with inflammatory bowel disease. Am. J. Gastroenterol. 97, 1755-1762. doi: 10.1111/j.1572-0241.2002.05837.x
92. Ponce, A. M., Vujaskovic, Z., Yuan, F., Needham, D., and Dewhirst, M. W. (2006). Hyperthermia mediated liposomal drug delivery. Int. J. Hyperthermia 22, 205-213. doi: 10.1080/02656730600582956
93. Poste, G., Papahadjopoulos, D., and Vail, W. J. (1976). Lipid vesicles as carriers for introducing biologically active materials into cells. Methods Cell Biol. 14, 33-71. doi: 10.1016/S0091-679X(08)60468-9
94. Puri, A., Loomis, K., Smith, B., Lee, J. H., Yavlovich, A., Heldman, E., et al. (2009). Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit. Rev. Ther. Drug Carrier Syst. 26, 523-580. doi: 10.1615/CritRevTherDrugCarrierSyst.v26.i6.10
95. Rahman, A. M., Yusuf, S. W., and Ewer, M. S. (2007). Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int. J. Nanomedicine 2, 567-583.
96. Ran, S., Downes, A., and Thorpe, P. E. (2002). Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res. 62, 6132-6140.
97. Riehemann, K., Schneider, S. W., Luger, T. A., Godin, B., Ferrari, M., and Fuchs, H. (2009). Nanomedicine-challenge and perspectives. Angew. Chem. Int. Ed Engl. 48, 872-897. doi: 10.1002/anie.200802585
98. Rip, J., Chen, L., Hartman, R., van den Heuvel, A., Reijerkerk, A., van Kregten, J., et al. (2014). Glutathione PEGylated liposomes: pharmacokinetics and delivery of cargo across the blood-brain barrier in rats. J. Drug Target. 22, 460-467. doi: 10.3109/1061186X.2014.888070
99. Sapra, P., and Allen, T. M. (2003). Ligand-targeted liposomal anticancer drugs. Prog. Lipid Res. 42, 439-462. doi: 10.1016/S0163-7827(03)00032-8
100. Sawant, R. R., and Torchilin, V. P. (2012). Challenges in development of targeted liposomal therapeutics. AAPS J. 14, 303-315. doi: 10.1208/s12248-012-9330-0
101. Schmitt, C. J., Dietrich, S., Ho, A. D., and Witzens-Harig, M. (2012). Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors. Ann. Hematol. 91, 391-397. doi: 10.1007/s00277-011-1308-y
102. Seiden, M. V., Muggia, F., Astrow, A., Matulonis, U., Campos, S., Roche, M., et al. (2004). A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer. Gynecol. Oncol. 93, 229-232. doi: 10.1016/j.ygyno.2003.12.037
103. Senior, J. H. (1987). Fate and behavior of liposomes in vivo: a review of controlling factors. Crit. Rev. Ther. Drug Carrier Syst. 3, 123-193.
104. Storm, G., ten Kate, M. T., Working, P. K., and Bakker-Woudenberg, I. A. (1998). Doxorubicin entrapped in sterically stabilized liposomes: effects on bacterial blood clearance capacity of the mononuclear phagocyte system. Clin. Cancer Res. 4, 111-115.
105. Suenaga, M., Mizunuma, N., Matsusaka, S., Shinozaki, E., Ozaka, M., Ogura, M., et al. (2015). Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study. Drug Des. Devel. Ther. 9, 3099-3108. doi: 10.2147/DDDT.S85567
106. Szebeni, J. (2005). Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 216, 106-121. doi: 10.1016/j.tox.2005.07.023
107. Szebeni, J., Alving, C. R., Rosivall, L., Bünger, R., Baranyi, L., Bedöcs, P., et al. (2007). Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles. J. Liposome Res. 17, 107-117. doi: 10.1080/08982100701375118
108. Szebeni, J., and Barenholz, Y. (2009). "Adverse immune effects of liposomes: complement activation, immunogenicity and immune suppression," in Harnessing Biomaterials for Nanomedicine: Preparation, Toxicity and Applications, ed P. S. Publishing (Singapore: Pan Stanford Publishing), 1-19.
109. Szebeni, J., Fontana, J. L., Wassef, N. M., Mongan, P. D., Morse, D. S., Dobbins, D. E., et al. (1999). Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. Circulation 99, 2302-2309. doi: 10.1161/01.CIR.99.17.2302
110. Szebeni, J., and Moghimi, S. M. (2009). Liposome triggering of innate immune responses: a perspective on benefits and adverse reactions. J. Liposome Res. 19, 85-90. doi: 10.1080/08982100902792855
111. Teli, M. K., Mutalik, S., and Rajanikant, G. K. (2010). Nanotechnology and nanomedicine: going small means aiming big. Curr. Pharm. Des. 16, 1882-1892. doi: 10.2174/138161210791208992
112. Tinkle, S., McNeil, S. E., Mühlebach, S., Bawa, R., Borchard, G., Barenholz, Y. C., et al. (2014). Nanomedicines: addressing the scientific and regulatory gap. Ann. N.Y. Acad. Sci. 1313, 35-56. doi: 10.1111/nyas.12403
113. Tirosh, B., Khatib, N., Barenholz, Y., Nissan, A., and Rubinstein, A. (2009). Transferrin as a luminal target for negatively charged liposomes in the inflamed colonic mucosa. Mol. Pharm. 6, 1083-1091. doi: 10.1021/mp9000926
114. Torchilin, V. P. (1994). Immunoliposomes and PEGylated immunoliposomes: possible use for targeted delivery of imaging agents. Immunomethods 4, 244-258. doi: 10.1006/immu.1994.1027
115. Torchilin, V. P., Klibanov, A. L., Huang, L., O'Donnell, S., Nossiff, N. D., and Khaw, B. A. (1992). Targeted accumulation of polyethylene glycol-coated immunoliposomes in infarcted rabbit myocardium. FASEB J. 6, 2716-2719.
116. Ulrich, A. S. (2002). Biophysical aspects of using liposomes as delivery vehicles. Biosci. Rep. 22, 129-150. doi: 10.1023/A:1020178304031
117. Vingerhoeds, M. H., Storm, G., and Crommelin, D. J. (1994). Immunoliposomes in vivo. Immunomethods 4, 259-272. doi: 10.1006/immu.1994.1028
118. Wang, X., Song, Y., Su, Y., Tian, Q., Li, B., Quan, J., et al. (2015). Are PEGylated liposomes better than conventional liposomes? A special case for vincristine. Drug Deliv. 29, 1-9. doi: 10.3109/10717544.2015.1027015
119. Webb, M. S., Saxon, D., Wong, F. M., Lim, H. J., Wang, Z., Bally, M. B., et al. (1998). Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine. Biomembranes 1372, 272-282. doi: 10.1016/S0005-2736(98)00077-7
120. Wetzler, M., Thomas, D. A., Wang, E. S., Shepard, R., Ford, L. A., Heffner, T. L., et al. (2013). Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia. Clin. Lymphoma Myeloma Leuk. 13, 430-434. doi: 10.1016/j.clml.2013.03.015
121. Willis, M., and Forssen, E. (1998). Ligand-targeted liposomes. Adv. Drug Deliv. Rev. 29, 249-271. doi: 10.1016/S0169-409X(97)00083-5
122. Wu, J., Lee, A., Lu, Y., and Lee, R. J. (2007). Vascular targeting of doxorubicin using cationic liposomes. Int. J. Pharm. 337, 329-335. doi: 10.1016/j.ijpharm.2007.01.003
123. Yarmolenko, P. S., Zhao, Y., Landon, C., Spasojevic, I., Yuan, F., Needham, D., et al. (2010). Comparative effects of thermosensitive doxorubicin-containing liposomes and hyperthermia in human and murine tumours. Int. J. Hyperthermia 26, 485-498. doi: 10.3109/02656731003789284
124. Zamboni, W. C., Ramalingam, S., Friedland, D. M., Edwards, R. P., Stoller, R. G., Strychor, S., et al. (2009). Phase I and pharmacokinetic study of pegylated liposomal CKD-602 in patients with advanced malignancies. Clin. Cancer Res. 15, 1466-1472. doi: 10.1158/1078-0432.CCR-08-1405
125. Zhang, H., Wang, G., and Yang, H. (2011). Drug delivery systems for differential release in combination therapy. Expert Opin. Drug Deliv. 8, 171-190. doi: 10.1517/17425247.2011.547470
126. Zhang, J. A., Anyarambhatla, G., Ma, L., Ugwu, S., Xuan, T., Sardone, T., et al. (2005). Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur. J. Pharm. Biopharm. 59, 177-187. doi: 10.1016/j.ejpb.2004.06.009
127. Zhang, J. A., Xuan, T., Parmar, M., Ma, L., Ugwu, S., Ali, S., et al. (2004). Development and characterization of a novel liposome-based formulation of SN-38. Int. J. Pharm. 270, 93-107. doi: 10.1016/j.ijpharm.2003.10.015
128. Zhang, L., Gu, F. X., Chan, J. M., Wang, A. Z., Langer, R. S., and Farokhzad, O. C. (2008). Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther. 83, 761-769. doi: 10.1038/sj.clpt.6100400
129. Zou, Y., Ling, Y. H., Van, N. T., Priebe, W., and Perez-Soler, R. (1994). Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties. Cancer Res. 54, 1479-1484.